Merck & Co’s Keytruda cancer immunotherapy could be set for another indication, which could open up for use in all cancer patients whose tumours have a certain genetic biomarker.
Bristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final part of a three-drug “bet” that was a sweetener following its $74 b
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
